• 8.75 % of all SYGNIS shares were tendered to dievini Hopp BioTech during the course of the offer • Resulting free float of SYGNIS Pharma AG approximately 33 %
Heidelberg, 27 January, 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) was informed of the final result of the mandatory offer made to all SYGNIS shareholders by dievini Hopp BioTech. During the course of the offer, which terminated on January 20, 2009, a total of 3,609,129 shares were tendered at a price of 1.44 Euro. This represents 8.75 % of the issued share capital (41,258,643 euros) and voting rights of SYGNIS Pharma AG.
Consequently, the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to a total of 18,526,822 shares and approximately 44.90% of the total share capital respectively. dievini Hopp BioTech thus remains the largest shareholder of SYGNIS Pharma AG, followed by BASF SE with 13.49%, Bayer AG with 3.39% and Dr. Friedrich von Bohlen und Halbach with 5.10%. Accordingly the free float of SYGNIS Pharma AG is 32.96% of the issued share capital.
About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development and marketing of innovative therapies for the treatment of disorders of the Central Nervous System. These include Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting from injuries to the brain or spinal cord. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available.
One of the central elements in this value-creation chain is the continued development of the existing product pipeline. This is achieved by testing the Company’s proprietary compounds which are already under development in a number of further CNS indications (“line extension”). By means of specific R&D programs at SYGNIS, new pre-clinical drug candidates are identified and evaluated and suitable CNS product candidates are also systematically tested for the purpose of acquisition or in-licensing.
For further information please contact: SYGNIS Pharma AG: Media contact: Dr. Franz-Werner Haas Julia Phillips Vice President Operations Financial Dynamics Tel: +49 (0) 6221 454 812 Tel: +44 (0) 20 7269 7187 franz-werner.haas@sygnis.de
